Fraser Valley Centre, British Columbia Cancer Centre, Surrey, BC, Canada.
Acta Oncol. 2010 Oct;49(7):1040-4. doi: 10.3109/0284186X.2010.509736.
PURPOSE/BACKGROUND: Validating a predictive model for late rectal bleeding following external beam treatment for prostate cancer would enable safer treatments or dose escalation. We tested the normal tissue complication probability (NTCP) model recommended in the recent QUANTEC review (quantitative analysis of normal tissue effects in the clinic).
One hundred and sixty one prostate cancer patients were treated with 3D conformal radiotherapy for prostate cancer at the British Columbia Cancer Agency in a prospective protocol. The total prescription dose for all patients was 74 Gy, delivered in 2 Gy/fraction. 159 3D treatment planning datasets were available for analysis. Rectal dose volume histograms were extracted and fitted to a Lyman-Kutcher-Burman NTCP model.
Late rectal bleeding (>grade 2) was observed in 12/159 patients (7.5%). Multivariate logistic regression with dose-volume parameters (V50, V60, V70, etc.) was non-significant. Among clinical variables, only age was significant on a Kaplan-Meier log-rank test (p=0.007, with an optimal cut point of 77 years). Best-fit Lyman-Kutcher-Burman model parameters (with 95% confidence intervals) were: n = 0.068 (0.01, +infinity); m =0.14 (0.0, 0.86); and TD50 = 81 (27, 136) Gy. The peak values fall within the 95% QUANTEC confidence intervals. On this dataset, both models had only modest ability to predict complications: the best-fit model had a Spearman's rank correlation coefficient of rs = 0.099 (p = 0.11) and area under the receiver operating characteristic curve (AUC) of 0.62; the QUANTEC model had rs=0.096 (p= 0.11) and a corresponding AUC of 0.61. Although the QUANTEC model consistently predicted higher NTCP values, it could not be rejected according to the χ(2) test (p = 0.44).
Observed complications, and best-fit parameter estimates, were consistent with the QUANTEC-preferred NTCP model. However, predictive power was low, at least partly because the rectal dose distribution characteristics do not vary greatly within this patient cohort.
目的/背景:验证一种用于预测前列腺癌外照射治疗后迟发性直肠出血的预测模型,将使治疗更安全或提高剂量。我们测试了最近 QUANTEC 综述(临床中正常组织效应的定量分析)中推荐的正常组织并发症概率(NTCP)模型。
161 例前列腺癌患者在不列颠哥伦比亚癌症中心前瞻性协议中接受 3D 适形放疗。所有患者的总处方剂量为 74 Gy,分 2 Gy/次给予。有 159 个 3D 治疗计划数据集可供分析。提取直肠剂量体积直方图,并拟合到 Lyman-Kutcher-Burman NTCP 模型中。
159 例患者中有 12 例(7.5%)发生迟发性直肠出血(>2 级)。多变量逻辑回归分析显示剂量-体积参数(V50、V60、V70 等)无统计学意义。在临床变量中,只有年龄在 Kaplan-Meier 对数秩检验中具有统计学意义(p=0.007,最佳截断点为 77 岁)。最佳拟合的 Lyman-Kutcher-Burman 模型参数(95%置信区间)为:n=0.068(0.01,+无穷大);m=0.14(0.0,0.86);TD50=81(27,136)Gy。峰值值落在 95%QUANTEC 置信区间内。在这个数据集上,这两个模型都只能适度地预测并发症:最佳拟合模型的斯皮尔曼等级相关系数 rs=0.099(p=0.11),接收器工作特征曲线(AUC)下面积为 0.62;QUANTEC 模型的 rs=0.096(p=0.11),相应的 AUC 为 0.61。尽管 QUANTEC 模型预测的 NTCP 值较高,但根据 χ(2)检验(p=0.44)不能拒绝。
观察到的并发症和最佳拟合参数估计与 QUANTEC 首选的 NTCP 模型一致。然而,预测能力较低,部分原因是直肠剂量分布特征在该患者队列中变化不大。